Eli Lilly Chases Weight Loss Fever, and Invests $3 Billion to Expand Its New US Plant

Eli Lilly is bulking up its production muscle. The American pharmaceutical company, one of the leaders in the market for injectable drugs for diabetes and obesity, has announced a new investment in the Wisconsin plant (United States) that it acquired last April .

Eight months ago, Eli Lilly spent $100 million to buy Nexus Pharmaceuticals’ plant in Kenosha. Now, the company says it will invest another $3 billion to expand the plant into a huge manufacturing complex for injectable drugs, including its obesity and diabetes drugs.

The new facility will also serve as a site for device assembly and drug packaging in multiple therapeutic areas. The factory currently employs 100 workers and with the expansion the workforce will rise to 750 workers.

Eli Lilly will employ 750 workers in its new factory, which will have 8,000 square meters

The expansion work will begin next year with the construction of nearly 8,000 square meters of additional space. This will be Eli Lilly’s largest industrial investment in the United States outside of its home state of Indiana.

Last October, Eli Lilly announced a $4.5 billion investment to expand its production in Indiana, focusing on developing new ways to produce its medicines and growing its experimental drugs.

Eli Lilly’s sales between July and September reached $11.439 billion, 20.4% more than a year earlier , with a growth of 46% in the United States, up to $7.81 billion, but a decline of 12% internationally, with $3.63 billion, due to the adverse effect of the exchange rate.

__

(Featured image by James Coleman via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us